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Background: Digital innovations in health care have traditionally followed a top-down pathway, with manufacturers leading
the design and production of technology-enabled solutions and those living with chronic conditions involved only as passive
recipients of the end product. However, user-driven open-source initiatives in health care are becoming increasingly popular. An
example is the growing movement of people with diabetes, who create their own “Do-It-Yourself Artificial Pancreas Systems”
(DIYAPS).
Objective: The overall aim of this study is to establish the empirical evidence base for the clinical effectiveness and quality-of-life
benefits of DIYAPS and identify the challenges and possible solutions to enable their wider diffusion.
Methods: A research program comprising 5 work packages will examine the outcomes and potential for scaling up DIYAPS
solutions. Quantitative and qualitative methodologies will be used to examine clinical and self-reported outcome measures of
DIYAPS users. The majority of members of the research team live with type 1 diabetes and are active DIYAPS users, making
Outcomes of Patients’ Evidence With Novel, Do-It-Yourself Artificial Pancreas Technology (OPEN) a unique, user-driven research
project.
Results: This project has received funding from the European Commission’s Horizon 2020 Research and Innovation Program,
under the Marie Skłodowska-Curie Action Research and Innovation Staff Exchange. Researchers with both academic and
nonacademic backgrounds have been recruited to formulate research questions, drive the research process, and disseminate
ongoing findings back to the DIYAPS community and other stakeholders.
Conclusions: The OPEN project is unique in that it is a truly patient- and user-led research project, which brings together an
international, interdisciplinary, and intersectoral research group, comprising health care professionals, technical developers,
biomedical and social scientists, the majority of whom are also living with diabetes. Thus, it directly addresses the core research
and user needs of the DIYAPS movement. As a new model of cooperation, it will highlight how researchers in academia, industry,
and the patient community can create patient-centric innovation and reduce disease burden together.
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Introduction
Type 1 diabetes (T1D) is a challenging chronic condition, which
often leads to lowered life expectancy and diminished quality
of life [1]. Despite significant advances in insulin therapy and
technological developments, only 17% of youth and 21% of
adults with diabetes achieve a glycated hemoglobin (HbA1c)
level of <7.0% (58 mmol/mol), as recommended in clinical
guidelines [2,3].
Closing the Loop: Automated Insulin Delivery Systems
In general, closed-loop insulin delivery systems, also called
“automated insulin delivery systems (AID)” or “artificial
pancreas systems (APS),” combine sensors for continuous
glucose monitoring (CGM) and insulin pumps with a control
algorithm, and these are characterized by automated insulin
delivery in response to the user’s glucose level. As
subcutaneously administered insulin stays active for multiple
hours, the algorithm used to calculate the amount of insulin
needed has to predict future glucose values to operate safely.
Closed-loop systems designed for commercial use have been
shown to be safe and effective in reducing hyperglycemia and
hypoglycemia in people with diabetes (PwD) of all age groups
[4-8], and these systems are therefore seen as the gold standard
of future diabetes therapy [9].
Qualitative research on commercially developed closed-loop
systems has indicated that individuals using these systems for
relatively short periods report reduced anxiety [10-14], improved
quality of sleep [10,14-17], and reduced burden of managing
diabetes [12,13,17-19] and this led to greater freedom and
flexibility in their lifestyle as a result [12,16-18]. This is
supported by a few quantitative studies that report less fear of
hypoglycemia [10-13,20,21]—although possibly because of
small sample sizes, the changes are not consistently
significant—a reduction in diabetes-specific distress in 2 studies
[13,20], and, in a single study, improved sleep quality [22].
These studies have used a range of closed-loop or
technology-specific quality-of-life instruments, with the
Diabetes Technology Questionnaire being the most widely used.
The Do-It-Yourself Artificial Pancreas:
#WeAreNotWaiting
However, although a variety of commercial APS are under
development and some have recently become available in a
limited number of countries, they are not universally available,
accessible, or affordable. Behind the hashtag
#WeAreNotWaiting, a community of PwD and their families
have created new tools and systems to help PwD better utilize
their devices and data. These systems are co-created in the
Do-It-Yourself Artificial Pancreas System (DIYAPS)
community, but each user has to build their own individual
system themselves and use at their own risk. Instructions and
code for these systems have been made universally available
via open-source platforms [23]. The DIYAPS or “Open-Source
Artificial Pancreas System” (OpenAPS) is one of the most
significant developments to emerge through this movement
[24]. In these systems, insulin delivery is automated and
remotely controlled by open-source algorithms and by reverse
engineering and connecting commercially available and
approved insulin pumps and CGM systems. The term “open
source” describes software whose source code is publicly
available. Open-source licenses usually deny liability and
warranty and may require disclosing source code and referring
to the project [25].
Initial observational studies on DIYAPS have described
significant improvements in glycemic control, quality of life,
and sleep quality in DIYAPS users of all age groups, including
children and adolescents, where caregivers build and maintain
these systems on their behalf [26-31]. A limited number of
studies are also specifically reporting on the experience of using
DIYAPS, and in addition to highlighting improved sleep
[28,30,32] and reduced burden of diabetes management [32],
they point to increased confidence, increased energy, and
reduced mood swings [32].
Evidence of usage of DIYAPS is limited to date, as none of
these systems have yet been evaluated by a randomized
controlled trial, regarding safety and efficiency—although at
least 1 is planned [33]. Observational studies largely describe
outcomes self-reported by users and are mainly based on smaller
cohort studies (up to n=80) [27]. There is an estimated 15+
million hours of real-world DIYAPS data, much of which have
yet to be fully analyzed. A global investigation based on
DIYAPS data is of interest to inform potential users of these
systems regarding the benefits and challenges of using the
system and to learn more about how clinical and quality-of-life
outcomes are affected by different groups of DIYAPS users, as
well as the mechanisms through which these results are being
achieved.
Another fundamental question is who might get left behind in
this user-driven technological innovation. DIYAPS aims to
better target the complexity of diabetes self-management for
the person with diabetes, reduce the cognitive and emotional
burden on PwD, and improve clinical outcomes. Such an
outcome would make an important contribution to reducing
inequalities in outcomes that are linked to individual disparities
in the capacity to cope with these burdens. However, there are
numerous challenges to be overcome to achieve this objective,
and the complexity of establishing and maintaining effective
DIYAPS currently remains high for many PwD. Thus, a further
challenge with respect to social inequality rests in how to ensure
that the benefits of APS are widely diffused across the
population so that no one is left behind in their diabetes care.
Therefore, the challenges in this area are not exclusively medical
or technical, but also ethical, sociological, and political in nature
and require an interdisciplinary and intersectoral approach to
be addressed effectively. Moreover, there is a rich vein of
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expertise and knowledge available from nontraditional experts
within the DIYAPS community, which has traditionally been
overlooked by both academia and industry. Successfully
bringing this nontraditional expertise into mainstream health
care settings is key to addressing some of the core research
opportunities and challenges that are likely to emerge as
do-it-yourself (DIY) solutions become increasingly popular and
shape digital innovations in diabetes care.
Objectives of the OPEN Project
Thus, the aim of the OPEN project (Outcomes of Patients’
Evidence With Novel, Do-It-Yourself Artificial Pancreas
Technology) is to examine what academia, industry, and PwD
can learn from one another, with the goal of making artificial
pancreas technology of all kinds available to everyone. The
OPEN consortium achieves this by bringing together an
intersectoral and interdisciplinary research team comprising
patient innovators, academic researchers in biomedical and
social sciences, health care professionals, and patient advocacy
organizations to establish an empirical evidence base
surrounding the impact of DIYAPS.
This collaboration is facilitated through a series of staff
exchanges between high-profile nonacademic organizations
dedicated to patient-driven approaches (Steno Diabetes Center
Copenhagen, Denmark; Dedoc Labs, Germany) and leading
research organizations in the field of diabetes research and
connected health (Charité—Universitätsmedizin Berlin,
Germany; University College Dublin, Ireland).
The central aims and objectives of the OPEN project have been
developed on the basis of the priorities of the DIYAPS and
wider diabetes communities. Furthermore, a key goal of the
OPEN project is to tap into the expertise of the DIYAPS
community to bring their knowledge and expertise to
mainstream health care settings.
OPEN is already co-led by some of the key members of the
DIYAPS movement and will actively continue to involve
members of the DIYAPS and wider diabetes communities to
facilitate their participation in OPEN, via staff secondments
and further collaborations. Furthermore, members of the
Diabetes Online Community are being recruited to assist with
disseminating the findings of the project on an ongoing basis




A total of 5 interdependent work packages (WPs) have been
proposed: The first 2 WPs are focused on acquiring data to
demonstrate what, if any, are the clinical, quality-of-life, and
psychosocial benefits of DIYAPS. This will include engaging
the community in sharing glucose and insulin dosing data, as
well as self-reporting on their experience of living with
DIYAPS. WP3 is focused on reducing the technical barriers to
DIYAPS. This also feeds into the work of WP4, which is
identifying the barriers to wider uptake of these user-led
innovations and exploring ways to reduce them. The final WP
relates to how the OPEN project will disseminate the results to
the research, health care, and community of PwD.
Work Package 1: Clinical Outcomes and Guidelines
The purpose of this WP is to evaluate the clinical outcomes of
DIYAPS users of all age groups globally and create a draft for
future guidelines for closed-loop technology in clinical routine.
Individuals using DIYAPS (any type) have the ability to
anonymously donate their data to research projects, via the
OpenAPS Data Commons, on the citizen science platform “Open
Humans” [31]. Users specifically consent to share their data for
research purposes, and they can choose to either manually
upload data of their choice or upload data via an upload tool of
their choice, with the data source of choice (for further details,
please see the description of WP3). The OPEN team will request
access to and utilize data from the OpenAPS Data Commons,
which is considered pseudonymized for purposes of the OPEN
project’s use.
Glycemic outcomes will be analyzed in a pre-post evaluation
of prospectively collected data from DIYAPS users. CGM
sensor data will be analyzed to calculate certain parameters,
such as the Time in Range (percentage of sensor glucose levels
between 70 mg/dL and 180 mg/dL) before and after DIYAPS
initiation as a primary key endpoint, as well as Time below
Range (<70 mg/dL, <54 mg/dL) and Time above Range (>180
mg/dL, >250 mg/dL) as secondary endpoints. Other secondary
key endpoints include self-reported parameters, such as HbA1c
levels, incidence of acute diabetes-related complications, such
as severe hypoglycemic events and incidence and possible cause
of diabetic ketoacidosis. Assessment of basic demographic and
health data, such as specifications of diabetes treatment,
socioeconomic status, gender, age, weight, height, comorbidities,
and incidence of diabetes-related complications, will enable
analysis of clinical outcomes for different user groups. To
further validate accuracy of self-reported clinical data from
patients and caregivers, data from a subcohort will be clinically
compared with independent medical data repositories to add to
the evidence base regarding the reliability of real-world data.
This WP is led by KB and KR, both PwDs and medical doctors
at the Department of Pediatric Endocrinology and Diabetes at
Charité University Medicine Berlin.
Work Package 2: Patient-Reported Outcomes
Alongside work to evaluate the clinical benefits of DIYAPS,
we will seek to establish the quality of life and lived experiences
of DIYAPS users. Given the lack of an internally consistent,
reliable, sensitive, and validated T1D-specific quality-of-life
questionnaire that also uses item wording that is widely
acceptable to people with T1D [34], the project will take a facet
approach to assessing the quality-of-life outcomes. For DIYAPS
users and their primary caregivers and loved ones, we will assess
the potential benefits of DIYAPS on emotional well-being, sleep
quality, hypoglycemia-related anxiety and fears, the burden of
diabetes, and flexibility of lifestyle. Furthermore, we will
investigate motivations, barriers, and retention factors to
building and maintaining DIYAPS in a questionnaire-based
survey and whether there are additional benefits accrued by
individuals assembling their own closed-loop systems [35,36].
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We will also explore effects on individuals’ sense of
self-efficacy, social support, and the benefits accrued from
joining a wider network of people with T1D.
In addition to the survey data on quality-of-life outcomes, the
project will also undertake qualitative research with DIYAPS
users to generate data about their lived experience with this
technology. An objective here is to examine how the lived
experiences of DIYAPS users vary across socioeconomic status,
gender, ethnicity, and age. To achieve this, a purposively
sampled select group of the project’s participants will be asked
to describe the day-to-day burden associated with T1D and
DIYAPS. Such burdens might include but not be limited to
out-of-pocket expenses, ability to carry out daily tasks in the
work setting or at home, participation in social activities and
other issues related to social connectedness, informal care
provided by family members or relatives, and episodes of
distress caused by living with diabetes. 
This WP is led by IW, BC, and TS, diabetes management
researchers at Steno Diabetes Center Copenhagen.
Work Package 3: Technical Development
This WP will focus on the evaluation and possible improvements
of DIYAPS through statistical and machine learning techniques.
The WP has 2 main objectives: (1) improving ease of use for
DIYAPS users’ data donation to support further research and
evaluation and (2) evaluating existing DIYAPS platforms and
implications for APS improvement.
We aim to improve DIYAPS users’ ability to donate data for
retrospective analysis for outcomes and future DIYAPS
developments. This is designed for those who are interested in
contributing to the DIYAPS community by donating their
anonymized datasets, as described in WP1 [37].
The current workflow enables individuals using DIYAPS to
upload data and contribute data anonymously to research, via
the Open Humans platform. Users can either do a manual upload
of their DIYAPS data, or they can utilize the “Nightscout Data
Transfer” tool to pull data directly from Nightscout into Open
Humans. Nightscout is an open-source remote monitoring
platform commonly used for real-time visualization of disparate
diabetes device data streams, also used for retrospective data
analysis and to report generation, which is widely used by
DIYAPS users [23]. Nightscout can capture behavioral data,
such as exercise entries, temporary targets to adjust DIYAPS
behavior, or meal entries, in addition to logging DIYAPS
predictions and output at 5-min intervals, and it becomes a rich
source for retrospective data analysis for research when donated
to the OpenAPS Data Commons. However, not all individuals
choose to use Nightscout, and other methods are therefore
planned to increase the ease of data donation for research. The
OPEN team also plans to add direct upload capabilities to one
of the commonly used DIYAPS (AndroidAPS) that will
authenticate directly with Open Humans and enable an
additional data donation method to the OpenAPS Data
Commons. The current uploading methods require the user to
initiate any subsequent data uploads; both methods described
above will permit users to opt in to enable automatic, regular
data uploads. This both makes data donation easier and captures
data that are often deleted, either accidentally or to free up
storage space for the user. After enabling increased data
donation with a wider and diverse population of DIYAPS users,
we expect the OpenAPS Data Commons available dataset to be
increased from about 115 users to an estimated 300 or more
users. As the dataset is based on real-world data, there may be
concerns about data integrity. However, data are processed and
connected in many ways with complex decision trees, which
makes it hard to falsify data. Furthermore, studies have shown
that real-world data are as robust as, if not more robust than,
data gathered in clinical trials with predefined selected
populations [38].
Although current studies have shown that DIYAPS users achieve
positive outcomes (clinical and quality of life) [26-31], there
are areas for improvement and further iteration in terms of
usability, algorithm features, and optimizing individual settings
and preferences, as well as areas of statistical learning, which
are applicable to all APS (DIY or commercially developed).
With several hundred (see above) pseudonymized datasets, we
expect to be able to break down outcome data into subcohorts
to better quantify the impact of different algorithm choices and
settings. This may include comparing outcomes among
individuals using varying versions of algorithms over time,
comparing different feature choices between and across
individuals, and evaluating settings (such as specifications of
medical devices and insulin, target values, specific feature use,
and mealtime dosing behaviors). This will enable identification
of less optimal use patterns in the real world, which will yield
recommendations for prioritization of future improvement areas
in development of DIYAPS, insight into the biggest needs of
varying subcohorts, and this also indicates the most popular or
most effective features in DIYAPS, which could also be
translated and adapted and inform the use of commercially
developed APS.
This WP is led by DL, PwD and founder of OpenAPS, and AT,
PwD and developer of AndroidAPS.
Work Package 4: Barriers to Scale-Up
This WP aims to explore the potential economic, social, cultural,
legal, and political barriers to the scale-up of DIYAPS
technology.
The first objective of this WP will be to examine the potential
barriers to uptake experienced by PwD who are interested in
DIYAPS but have so far opted not to build their own system,
have opted out after an unsuccessful attempt, or otherwise
chosen to discontinue DIYAPS. We observe that many people
stay connected to the online DIYAPS community regardless of
their initial choice to use DIYAPS or not, as indicated by the
10,000+ people participating in the main “Looped” group on
Facebook, as compared with the estimated, approximately 3000
likely active users of DIYAPS. Members of the Facebook peer
support group “Looped” and other related Facebook groups
who have yet to build their own system will therefore be targeted
through questionnaires that aim to capture the reasons for not
doing so. The questionnaires will probe for indicators, such as
lack of knowledge of the benefits of using DIYAPS, lack of
confidence in one’s own information technology (IT) skills,
affordability of technologies, time and effort needed to build
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DIYAPS, and other reasons for stopping DIYAPS, such as the
availability of a commercial solution or lack of support from
health care providers. The content of these questionnaires will
be generated on the basis of a list of potential barriers to uptake,
identified through the findings from WP2 [35,36] and qualitative
in-depth interviews with a targeted sample of non-DIYAPS
users. The overall outcome will be a greater understanding of
the reasons why these individuals are not yet using DIYAPS or
have chosen not to use DIYAPS, which will consequently help
researchers to develop better ways of addressing barriers to
access and adoption of APS.
The next defining point of this WP is committed to
understanding the health equity implications associated with
the progression of DIY technology-enabled solutions for chronic
disease management. More specifically, we aim to capture the
requirements of DIYAPS users with lower levels of IT literacy.
This will be established through a series of one-to-one and focus
group interviews. The interviews will inform the development
of low-fidelity wireframes that can be demonstrated at
user-experience design workshops for further feedback from
less tech-savvy DIYAPS users. The result will be a series of
use cases that will be made available for the benefit of DIYAPS
developers and the medical device industry.
An additional aspect of WP4 is to examine the current extent
to which there are observable social inequalities in terms of
access to the technologies needed to build DIYAPS and how
these inequalities might be addressed and minimized. From this
perspective, we will utilize data from the T1International
Out-of-Pocket Expenses survey to examine the
out-of-pocket-expenses and other accessibility issues associated
with DIYAPS-related technologies [39].
This WP is led by SO, PwD and sociologist at the School of
Sociology, University College Dublin.
An overview of 4 scientific work packages is provided in
Multimedia Appendix 1.
Work Package 5: Communication and Dissemination
This WP will coordinate the training, communication, and
dissemination activities of the OPEN project and its aims to
ensure high visibility and direct impact in the community,
involving relevant stakeholders. The objectives include (1)
implementing dissemination actions and communication
activities to targeted audiences, (2) promoting the project
concept and vision by highlighting its unique structure
connecting patient researchers and innovators with established
research organizations through social media, workshops, our
newsletter, and the project website, (3) ensuring technical and
scientific dissemination of the project results through
publications in journals and conferences, and (4) raising public
awareness of the project’s objectives.
Different target audiences will be engaged with information
adjusted carefully to their needs, raising awareness among those
who can benefit from the project results and encouraging
multistakeholder dialogue. The consortium has identified
potential target groups, including the scientific community,
clinicians and health care professionals, PwD, the DIYAPS
community, policy makers and regulators, the medical and IT
industry, and the general public.
All academic outputs that result from this project will be
published in open-access journals and on the project’s public
dissemination channels. Conference presentations at academic,
clinical, and industry events provide an important opportunity
for researchers to disseminate findings to multiple audiences.
DIYAPS is currently a hot topic within diabetes care, and
face-to-face interaction with conference delegates presents an
opportunity to generate dialogue among both the proponents
and critics of DIYAPS. This consortium will not only contribute
to a body of evidence that will help to move the terms of the
discussion forward but it will also ensure that the patient voice
remains center stage.
Social media will also be used to ensure that the project findings
reach multiple stakeholders and that the findings will influence
decisions in public policy and professional practice. Twitter,
LinkedIn, Facebook, and YouTube will be used as dissemination
vehicles, providing a headline or snapshot summaries of key
takeaway messages from the project outcomes, which will attract
the attention of key stakeholders. Scheduled dissemination and
communication activities will be held throughout the duration
of the project to ensure constant information flow. Targeted
messages will be distributed to the public to ensure that impact
is maximized.
Finally, it is important to note that any technical innovations
that might emerge or evolve from this project will be shared
with the public, including DIYAPS developers, and it will
ultimately be their decision whether to use the findings of OPEN
as the basis to implement any changes in DIYAPS, as our role
is focused solely on research and establishing an evidence base.
Thus, the organizations’ efforts in this project are not directly
involved in, and will remain separated from, any direct DIYAPS
development.
This WP is led by BH, PwD and CEO of Dedoc Labs.
Results
This project has received funding from the European
Commission’s Horizon 2020 Research and Innovation Program,
under the Marie Skłodowska-Curie Action Research and
Innovation Staff Exchange grant agreement number 823902.
Initial results on clinical outcomes and patient-reported
outcomes have been presented at the Advanced Diabetes
Technologies and Treatments Conference in February 2019 in
Berlin, Germany, and the American Diabetes Association 79th
Scientific Sessions in San Francisco, the United States, in June
2019 [35,36,40,41]. A study on self-reported clinical outcomes
of the pediatric population using DIYAPS has been recently
published in JMIR mHealth and uHealth [26], showing
improved glycemic outcomes across all pediatric age groups,
which is in line with clinical trial results from commercially
developed closed-loop systems.
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DIYAPS represents an important case study in how increasingly
informed and connected patients are shaping the direction of
technological innovation in diabetes care and, potentially, for
other areas of health care. As outlined above, researching this
global movement poses unique challenges and opportunities,
which necessitate a move away from traditional, top-down
modes of scientific inquiry toward a more cooperative and
interactive approach, which is largely driven by PwD
themselves.
The OPEN project is uniquely placed to address these
challenges, as it is a patient- and user-led research project that
brings together an international, interdisciplinary, and
intersectoral research group comprising health care
professionals, technical developers, and biomedical and social
scientists, many of whom live with diabetes and are active
DIYAPS users. Thus, the OPEN consortium is poised to bring
the benefits of expertise of all kinds combined with the
prioritization and knowledge of on-the-ground patient needs in
a way that, to the best of our knowledge, is not being addressed
by other research projects and collaborative initiatives.
It is acknowledged that the nature of the OPEN project can pose
potential limitations and challenges. For example, the clinical
evaluation (WP1) may be potentially seen as lacking rigor
because of its inclusion and use of user-provided data. However,
it is precisely this aspect of our methodological approach which
has the potential to make a significant contribution to the extant
literature surrounding the effectiveness of APS technology.
Most studies on APS technology, to date, have been carried out
as randomized clinical trials in well-controlled clinical research
settings. Therefore, little is known about efficacy of APS in
real-world settings where outcomes are likely to be contingent
on context [42]. Moreover, previous studies have, for the most
part, focused on measuring biomedical disease
specific–outcomes; therefore, many other consequences of using
closed-loop systems, such as psychosocial outcomes, remain
relatively poorly understood [43]. By being one of the first
studies to generate evidence on the basis of reliable,
user-provided data from all 3 DIYAPS (OpenAPS, AndroidAPS,
and Loop) in real-world settings, this study will be an important
complement to the existing clinically led research studies in the
field.
In this regard, it is important to point out that both positive and
negative forms of evidence surrounding DIYAPS will be valued
equally by the OPEN team. Negative results provide important
learning opportunities for the further development and diffusion
of APS technology and for understanding what works, for
whom, and under what set of circumstances [44]. This is why
WPs around barriers (WP4), outcomes across a broad population
(WP1 and WP2), and improvements to technology (WP3) have
been designed. For example, qualitative studies exploring the
lived experience of DIYAPS users (WP2) will seek out instances
where individuals have used a closed-loop system but
subsequently discontinued use. Finally, although negative results
tend to be underreported in much of the traditional evaluation
research literature [45], the OPEN team will openly share and
attempt to publish all results from each WP.
Overall, by providing empirical evidence on DIYAPS, this
project addresses the core user needs of the DIYAPS
community. In addition, it will offer insights around accelerating
improvements and diffusion of APS technology across the wider
population of PwD. Disseminating project results in academic
and nonacademic settings will help lower barriers among key
stakeholders and encourage other researchers, policy makers,
regulators, and the medical device industry to work together
and innovate in a truly patient- and user-centric manner. We
believe this new model of cooperation has the potential to have
a profound impact on those living with diabetes, their families,
health care systems, and society as a whole.
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